Complications and risk factors in transrectal ultrasound-guided prostate biopsies

Sao Paulo Medical Journal

Volumn 124, Issue 4, 2006, Pages 198-202

  Nóbrega de Jesus, Carlos Márcio ^a   Corrêa, Luiz Antônio ^a   Padovani, Carlos Roberto ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Needle biopsy; Prostate; Prostatic neoplasms; Risk factors; Ultrasonography

Indexed keywords

ACETYLSALICYLIC ACID; CIPROFLOXACIN; PROSTATE SPECIFIC ANTIGEN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BACTERIURIA; BLADDER CATHETERIZATION; BLEEDING; CATHETER INFECTION; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; DRUG CONTRAINDICATION; DRUG USE; DYSURIA; FEVER; HEMATOCHEZIA; HEMATURIA; HEMOSPERMIA; HUMAN; HYPERTENSION; INDWELLING CATHETER; INFECTION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; ORCHITIS; PATIENT SAFETY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATITIS; RECTUM HEMORRHAGE; RISK FACTOR; SEPSIS; SHIVERING; TRANSRECTAL ULTRASONOGRAPHY; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION;

EID: 33750953597     PISSN: 15163180     EISSN: 15163180     Source Type: Journal    
DOI: 10.1590/s1516-31802006000400005     Document Type: Article

References (22)

1. American Cancer Society. Overview: Prostate Cancer. How Many Men Get Prostate Cancer? Available from URL: http://www.cancer.org/docroot/ CRI_2_2_1X_Hown_many_men_get_prostate_cancer_36.asp?sitearea. Accessed in: 2006 (Jul 31).
2. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1989;159(4):1247-50.
3. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol. 1997;158(5):1886-90.
4. Rifkin MD, Alexander AA, Pisarchick J, Matteucci T. Palpable masses in the prostate: superior accuracy of US-guide biopsy compared with accuracy of digitally guided biopsy. Radiology. 1991;179(1):41-2.
5. Clements R, Aideyan OU, Griffiths GJ, Peeling WB. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol. 1993;47(2):125-6.
6. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998;160(6 Pt 1):2115-20.
7. Irani J, Fournier F, Bon D, Gremmo E, Dore B, Aubert J. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br J Urol. 1997;79(4):608-10.
8. Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity and patient acceptance. Br J Urol. 1993;71(4):460-3.
9. Lee F, Torp-Pedersen S, Littrup PJ, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology. 1989;170(1 Pt 1):29-32.
10. Hodge KK, McNeal JE, Terris MK, Starney TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142(1):71-4; discussion 74-5.
11. Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52(4):552-8.
12. Aus G, Ahlgren G, Bergdahl S, Hugosson J. Infection after transrectal core biopsies of the prostate - risk factors and antibiotic prophylaxis. Brit J Urol. 1996;77(6):851-5.
13. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164(2):388-92.
14. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60(5):826-30.
15. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997;49(6):875-80.
16. Sieber PR, Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Harpster LE. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997;157(6):2199-200.
17. Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of prospective European prostate cancer detection study. J Urol. 2001;166(3):856-60.
18. Deliveliotis C, John V, Louras G, et al. Multiple transrectal ultrasound guided prostatic biopsies: morbidity and tolerance. Int Urol Nephrol. 1999;31(5):681-6.
19. Fong IW, Struthers N, Honey RJ, Simbul M, Boisseau DA. A randomized comparative study of the prophylactic use of trimethoprim-sulfamethoxazole versus netilmycin-metronidazole in transrectal prostatic biopsy. J Urol. 1991;146(3):794-7.
20. Ruebush TK 2nd, McConville JH, Calia FM. A double-blind study of trimethoprim-sulfamethoxazole prophylaxis in patients having transrectal needle biopsy of the prostate. J Urol. 1979;122(4):492-4.
21. Ravery V, Billebaud T, Toublanc M, et al. Diagnostic value of ten systematic TRUS-guided prostate biopsies. Eur Urol. 1999;35(4):298-303.
22. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 1998;159(2):471-5; discussion 475-6.